Your browser doesn't support javascript.
loading
Durability of Tricuspid Valve Repair in Patients Undergoing Left Ventricular Assist Device Implantation.
Färber, Gloria; Schwan, Imke; Kirov, Hristo; Rose, Marcel; Tkebuchava, Sophie; Schneider, Ulrich; Caldonazo, Tulio; Diab, Mahmoud; Doenst, Torsten.
Afiliação
  • Färber G; Department of Thoracic and Cardiovascular Surgery, Saarland University Medical Center, 66421 Homburg/Saar, Germany.
  • Schwan I; Department of Cardiothoracic Surgery, Jena University Hospital, Friedrich-Schiller-University Jena, 07743 Jena, Germany.
  • Kirov H; Department of Thoracic and Cardiovascular Surgery, Saarland University Medical Center, 66421 Homburg/Saar, Germany.
  • Rose M; Department of Cardiothoracic Surgery, Jena University Hospital, Friedrich-Schiller-University Jena, 07743 Jena, Germany.
  • Tkebuchava S; Department of Cardiothoracic Surgery, Jena University Hospital, Friedrich-Schiller-University Jena, 07743 Jena, Germany.
  • Schneider U; Department of Cardiothoracic Surgery, Jena University Hospital, Friedrich-Schiller-University Jena, 07743 Jena, Germany.
  • Caldonazo T; Department of Cardiothoracic Surgery, Jena University Hospital, Friedrich-Schiller-University Jena, 07743 Jena, Germany.
  • Diab M; Department of Thoracic and Cardiovascular Surgery, Saarland University Medical Center, 66421 Homburg/Saar, Germany.
  • Doenst T; Department of Cardiothoracic Surgery, Jena University Hospital, Friedrich-Schiller-University Jena, 07743 Jena, Germany.
J Clin Med ; 13(5)2024 Feb 29.
Article em En | MEDLINE | ID: mdl-38592251
ABSTRACT

Objectives:

Benefits of tricuspid valve repair (TVR) in left ventricular assist device (LVAD) patients have been questioned. High TVR failure rates have been reported. Remaining or recurring TR was found to be a risk factor for right heart failure (RHF). Therefore, we assessed our experience.

Methods:

Since 12/2010, 195 patients have undergone LVAD implantation in our center. Almost half (n = 94, 48%) received concomitant TVR (LVAD+TVR). These patients were included in our analysis. Echocardiographic and clinical data were assessed. Median follow-up was 2.8 years (7 days-0.6 years). Results were correlated with clinical outcomes.

Results:

LVAD+TVR patients were 59.8 ± 11.4 years old (89.4% male) and 37.3% were INTERMACS level 1 and 2. Preoperative TR was moderate in 28 and severe in 66 patients. RV function was severely impaired in 61 patients reflected by TAPSE-values of 11.2 ± 2.9 mm (vs. 15.7 ± 3.8 mm in n = 33; p < 0.001). Risk for RHF according to EUROMACS-RHF risk score was high (>4 points) in 60 patients, intermediate (>2-4 points) in 19 and low (0-2 points) in 15. RHF occurred in four patients (4.3%). Mean duration of echocardiographic follow-up was 2.8 ± 2.3 years. None of the patients presented with severe and only five (5.3%) with moderate TR. The vast majority (n = 63) had mild TR, and 26 patients had no/trace TR. Survival at 1, 3 and 5 years was 77.4%, 68.1% and 55.6%, 30-day mortality was 11.7% (n = 11). Heart transplantation was performed in 12 patients (12.8%).

Conclusions:

Contrary to expectations, concomitant TVR during LVAD implantation may result in excellent repair durability, which appears to be associated with low risk for RHF.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: J Clin Med Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: J Clin Med Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha